English-language fact-check editor

English-language fact-check editor

The editor will focus on misinformation in Asia and edit fact-checking stories from around the region. Applicants must have strong digital investigation skills and demonstrated experience in digital verification techniques and tools. Strong editing skills and solid news judgement are a must. Asian languages are a plus.

FINNISH-LANGUAGE FACT-CHECK REPORTER/JOURNALIST

FINNISH-LANGUAGE FACT-CHECK REPORTER/JOURNALIST

The role is an exciting opportunity to be a part of AFP's fast-growing fact-checking network, which has seen it take a leading role in the global fight against disinformation.

The position requires an agile journalist who can easily navigate online disinformation, mostly on Facebook but also other major social media platforms such as Instagram, Twitter, YouTube or TikTok.

11/05/2025 21:04
IonQ and Swiss Consortium Launch First Citywide Dedicated Quantum Network in Geneva

IonQ (NYSE: IONQ), the world’s leading quantum company, with luminary Swiss partners, successfully deployed a citywide quantum network in Geneva, Switzerland. This consortium of world-class academic, enterprise, and public institutions will advance quantum cybersecurity and communications research, collaboration, and innovation. The new infrastructure, named the Geneva Quantum Network (GQN), is the nation’s first dedicated quantum network connecting key institutions across the region. “Our inv...

11/12/2025 07:04
Exstent Appoints Matt Thompson as CEO to Drive Global Growth in Personalised Aortic Support

Exstent, a UK-based medical device company, developing personalised external aortic support to preserve the native aorta, today announced the appointment of Matt Thompson as Chief Executive Officer to lead its next phase of global growth. Matt brings more than two decades of combined clinical and commercial leadership to Exstent. He previously held leadership roles including President and CEO at Endologix, guiding the company through transformation, portfolio growth, and the 2021 acquisition ...

11/18/2025 06:00
Avanzanite Bioscience Secures €32M Series A Investment from MVM Partners

Avanzanite Bioscience B.V. (Avanzanite), a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today announced a €32 million Series A growth investment from MVM Partners (MVM), a leading global life-science private equity firm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251117345890/en/Adam Plich, Founder and CEO of Avanzanite. The announcement follows a record-breaking Q3 2025 fo...